Clinical trial · Observational
Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
NCT07549269CI-TRIAL-00123479completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used. However, there is currently no definitive evidence comparing the efficacy of these two agents in the context of neoadjuvant therapy for ESCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel. | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Nab-P cohort
- interventionNames
- Drug: The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.
- label
- PTX cohort
- interventionNames
- Drug: The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.
Primary outcomes (3)
- measure
- PCR
- timeFrame
- Within 4 weeks after surgery
- description
- Pathological Complete Response
- measure
- DFS
- timeFrame
- From the date of esophagectomy until the date of first documented disease recurrence, disease progression, or death from any cause, whichever came first, assessed up to 60 months.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC). 2. Patients with resectable or potentially resectable disease based on baseline clinical assessment. Exclusion Criteria: 1. Presence of any untreated malignancy within the past five years, except fully treated cervical carcinoma in situ or basal cell carcinoma/squamous cell skin cancer. 2. Receipt of other neoadjuvant treatments, including chemotherapy, chemoradiotherapy, or chemoradiotherapy combined with immunotherapy. Incomplete medical records. 3. Refusal to participate in follow-up.
References
Publications (0)
Data not yet available
No reference posted for this study.